News

The last patient has completed the last study visit in the withdrawal phase of the Phase 3 LOGICS clinical trial that is investigating the safety and effectiveness of Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome. The announcement by Strongbridge Biopharma, the therapy’s developer, says that LOGICS…

The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…

The proportion of Cushing’s syndrome patients whose disease is caused by a tumor in the adrenal glands is higher in Asia than in other continents. Now, researchers in Thailand suggest that countries in Southeast Asia also may have a higher incidence of this subtype of cases. The research, “…

Recordati’s Isturisa (osilodrostat) safely and effectively normalizes urinary levels of cortisol in people with endogenous Cushing’s syndrome other than Cushing’s disease, according to data from a Phase 2 clinical trial in Japan. Endogenous Cushing’s syndrome occurs when the body produces abnormally high levels of the…

Isturisa (osilodrostat), an approved therapy for Cushing’s disease, continues to demonstrate high and sustained responses in patients for whom pituitary gland surgery is not an option or whose disease returned after surgery, findings from a Phase 3 trial show. The LINC-4 study (NCT02697734) showed that significantly more patients…

The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during the COVID-19 pandemic, the organization recently announced. The grants will support activities that align with the foundation’s Rare Belonging focus, a set of funding priorities aimed at improving the…

Infection with COVID-19 may appear different and take a distinct clinical course in people with Cushing’s syndrome than in other patients, according to an international team of researchers. Despite an absence of data about the effects of COVID-19 on this high-risk group, researchers from…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.

Cushing’s syndrome treatment Isturisa (osilodrostat) now is commercially available in France. The announcement from Recordati Rare Diseases comes soon after the medication became fully available for sale and distribution to adults in the U.S. The company stated that the medication will be made available elsewhere in the European Union…

Isturisa (osilodrostat) oral treatment for Cushing’s disease patients is now fully available to be sold and distributed across the United States, according to its developer Recordati Rare Diseases. The move follows Isturisa’s recent approval by the U.S. Food and Drug Administration (FDA) for adult…